01730nam a2200253 4500 ESSALUD 20260805002026.0 ta t pe ||||| |||| 00| 0 spa d BMG eng Du Toit, George Autor 53889 Prevention and treatment of peanut allergy páginas: 2449-2458 Early introduction of peanut protein reduces allergy prevalence by approximately 80%, with efficacy diminishing as introduction is delayed. Appropriate prevention involves ingestion of approximately 2 g of peanut protein weekly for infants at low risk and 4 to 6 g weekly for infants at high risk. Population-level implementation that targets all infants achieves greater reduction in disease burden than approaches that target only high-risk groups, although disparities exist among some ethnic groups and groups with restricted access to care. Peanut immunotherapy initiated in younger children (1 to 3 years of age) shows superior efficacy and higher rates of clinical remission as compared with immunotherapy initiated in older children. The natural history of untreated peanut allergy follows a trajectory of increasing peanut-specific IgE levels and clinical reactivity over time, underscoring the importance of early intervention during this narrow developmental window. ALERGIA 7055 DERMATOLOGÍA 7479 MEDICINA CLINICA 33681 ENFERMEDADES INFANTILES 53890 NUTRICIÓN Lack, Gideon 53891 22717 22639 Massachusetts NEJM Group NEJM006 The New England Journal of Medicine ESSALUD 0028-4793 ARTICULOS 2026-07-31 SQB 22764 22764